Merit Medical Beats Expectations in Q1 2026, Yet Stock Still Trades at a Discount to 52‑Week High

Merit’s Q1 numbers show a company that is still growing its core business despite a crowded interventional‑device market. Reported revenue rose 7% to $381.9 million, while constant‑currency revenue, which strips out foreign‑exchange effects, grew 5% and organic constant‑currency revenue climbed 3% after excluding the DualCap® divestiture. The modest top‑line expansion reflects the company’s shift to a two‑category revenue presentation—Foundational and Therapeutic—intended to give investors clearer insight into product mix and pricing power. The Therapeutic segment, which now includes the newly acquired OneMark® system, posted a 10% revenue increase, signaling early traction for the oncology‑focused acquisition.

Profitability improved on a non‑GAAP basis, with operating margin expanding to 19.7% from 19.3% a year ago and non‑GAAP EPS rising 9% to $0.94. GAAP EPS, however, surged 39% to $0.68, driven largely by a $12.5 million gain on the DualCap® asset sale and lower tax expense. Free cash flow jumped 26% to $24.7 million, underscoring the cash‑generating nature of the business and providing headroom for debt repayment or further strategic investments. The company’s balance sheet now shows $488 million in cash against $747 million of total debt, with borrowing capacity of roughly $697 million, a comfortable cushion for the remainder of its Continued Growth Initiatives Program.

The acquisition of View Point Medical for $140 million, of which $90 million was paid in cash, adds the OneMark® Detection Imaging System and tissue markers to Merit’s therapeutic oncology portfolio. Management expects the deal to contribute $2‑$4 million of incremental revenue in 2026 and to be marginally dilutive to non‑GAAP EPS by about $0.05, after accounting for interest expense on the cash used for the purchase. While the revenue impact is modest, the acquisition is positioned as a margin‑accretive foothold in a high‑growth oncology market, where procedural volumes and reimbursement rates are expanding.

From an investor perspective, the stock is trading at $68.18, roughly 31.9% below its 52‑week high of $100.19 and only 6.9% above its 52‑week low of $63.78. Technical indicators paint a mixed picture: the 14‑day RSI sits at 49.8, suggesting neutral momentum, while the price remains below both the 50‑day (96.1% of SMA) and 200‑day (83.7% of SMA) moving averages, indicating a bearish trend. However, relative volume is nearly double its average, hinting at heightened interest following the earnings release. Analysts’ consensus price target of $100.14 implies an upside of about 47%, but that potential is contingent on the successful integration of View Point’s assets and the continued execution of Merit’s growth initiatives.

Risks remain. The company flagged exposure to trade policy volatility, integration challenges, and the need for continued product adoption in a competitive landscape. Additionally, the modest 5‑7% full‑year revenue guidance (now $1.612‑$1.634 billion) leaves little room for error; any slowdown in therapeutic sales or unforeseen cost pressures could pressure margins. Nevertheless, the combination of a growing cash base, disciplined cost structure, and a strategic focus on high‑margin oncology products provides a compelling narrative for investors seeking exposure to the medical‑device sector at a discount.

In summary, Merit delivered a beat‑and‑raise earnings story that aligns with its guidance, while the stock’s current valuation suggests a sizable upside if the company can sustain its margin improvements and realize the expected benefits from its recent acquisition. Investors should monitor the integration progress of the OneMark system, the impact of the DualCap® divestiture on cash flow, and broader macro‑economic factors that could affect device pricing and reimbursement.